NASDAQ:NEOS - Neos Therapeutics Stock Price, News & Analysis

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Neos Therapeutics Inc (NASDAQ:NEOS) released its earnings results on Thursday, August, 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.09. The business had revenue of $15.64 million for the quarter, compared to analyst estimates of $16.70 million. View Neos Therapeutics' Earnings History.

Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Neos Therapeutics.

4 Wall Street analysts have issued 12-month price targets for Neos Therapeutics' stock. Their forecasts range from $3.00 to $10.00. On average, they expect Neos Therapeutics' stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 287.7% from the stock's current price. View Analyst Price Targets for Neos Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neos Therapeutics.

Headlines about NEOS stock have trended negative on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Neos Therapeutics earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Neos Therapeutics.

Some companies that are related to Neos Therapeutics include Innate Pharma (IPHYF), AC Immune (ACIU), Corbus Pharmaceuticals (CRBP), Merus (MRUS), Puma Biotechnology (PBYI), Avid Bioservices (CDMO), Provention Bio (PRVB), Beyondspring (BYSI), MediciNova (MNOV), resTORbio (TORC), Mallinckrodt (MNK), Akorn (AKRX), XBiotech (XBIT), Organogenesis (ORGO) and Arcus Biosciences (RCUS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Fibrocell Science (FCSC), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), TG Therapeutics (TGTX), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), BioDelivery Sciences International (BDSI), Amicus Therapeutics (FOLD), Melinta Therapeutics (MLNT) and ACADIA Pharmaceuticals (ACAD).

(NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

Neos Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (10.00%), Vanguard Group Inc. (4.02%), BlackRock Inc. (1.07%), Northern Trust Corp (1.00%), Morgan Stanley (0.84%) and Alambic Investment Management L.P. (0.44%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View Institutional Ownership Trends for Neos Therapeutics.

NEOS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Charles Schwab Investment Management Inc., Vanguard Group Inc., Northern Trust Corp and Wells Fargo & Company MN. View Insider Buying and Selling for Neos Therapeutics.

NEOS stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Paloma Partners Management Co, Alambic Investment Management L.P., JPMorgan Chase & Co., Jane Street Group LLC, Morgan Stanley, Algert Global LLC and D. E. Shaw & Co. Inc.. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View Insider Buying and Selling for Neos Therapeutics.

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NEOS stock can currently be purchased for approximately $1.87.

Neos Therapeutics has a market capitalization of $93.00 million and generates $49.99 million in revenue each year. The company earns $-51,670,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe.View Additional Information About Neos Therapeutics.

The official website for Neos Therapeutics is http://www.neostx.com/.

Neos Therapeutics' mailing address is 2940 N. HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]